Dr. Divya Srivastava, MD

Dr. Srivastava practices at UT of Texas Southwestern University Hospital - William P. Clements Jr. - HOPD (5939 Harry Hines Blve) in Dallas, Texas.

Dr. Srivastava's NPI, 1689875825, was assigned on May 29, 2007. Dr. Srivastava graduated from New York University School of Medicine in 2005. Dr. Srivastava's Michigan license number on file is 4301087723.

Dr. Srivastava's primary practice is UT of Texas Southwestern University Hospital - William P. Clements Jr. - HOPD (5939 Harry Hines Blve), at 5939 Harry Hines Blve, Dallas, TX 75235.

Dr. Srivastava's primary practice is UT of Texas Southwestern University Hospital - William P. Clements Jr. - HOPD (5939 Harry Hines Blve) in Dallas, Texas. Dr. Srivastava is also affiliated with William P. Clements Jr. University Hospital. The medical group on file is University of Texas Southwestern Medical Center. Dmand AI also links Dr. Srivastava to 1 more hospital and 1 group practice or clinic, each named with a free account. Dr. Srivastava's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Srivastava practices, 4 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Srivastava's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Srivastava is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Srivastava's licenses on file in 3 states: Michigan, California and Texas.

Dmand AI lists benign or precancerous skin growths and cancerous skin growth removal among the conditions Dr. Srivastava treats.

CMS data shows 2,414 Medicare services from Dr. Srivastava across 30 procedure codes in 2024, for 629 Medicare patients. Medicare paid $602,801 for them. Every service was in an office.

CMS counts 629 Medicare patients who saw Dr. Srivastava in 2024. The largest group is 75 to 84, with 276 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.51, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Srivastava's median patient age at 75, with 39% women.

In 2024, Dr. Srivastava wrote 88 Medicare Part D claims for 76 patients. 100% of them were for generic drugs. CMS names the drug for 70 of them, across 2 drugs with 11 or more claims each, at $718 in total drug cost. In 2023, CMS named 58 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Srivastava for performance year 2024, reported as part of a group. Dr. Srivastava accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Srivastava as offering telehealth. CMS counts 119 procedures of melanoma (skin cancer) excision by Dr. Srivastava, more than 94% of the clinicians it reports for that procedure.

Removal of nail tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 156 papers to Dr. Srivastava, published from 2010 to 2025. 2021 was the busiest year, with 20. The most frequent topics are Skin Neoplasms, Mohs Surgery and Carcinoma, Squamous Cell. Dr. Srivastava has published most often in Dermatol Surg. Dr. Srivastava's most frequent co-authors are Rajiv I. Nijhawan, MD, Andrew Matsumoto, MD and Lindsey West, MD.

CMS Open Payments shows 7 general payments to Dr. Srivastava from 4 drug and device companies from 2016 to 2023. Food and beverage make up the largest share, 100% of the total. Abbvie Inc. paid the most, $348.

Dmand AI lists 3 awards for Dr. Srivastava, most recently CMS Stage 1 EHR in 2012.

Dr. Srivastava graduated from New York University School of Medicine in 2005. Dr. Srivastava is a member of AAD and ASDS.

Dr. Srivastava is in network with 22 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 14. Check the plan with the practice before a visit.